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A comparison of the lung deposition
of budesonide from Easyhaler1,Turbuhaler1 and
pMDI plus spacer in asthmatic patients
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Abstract Inhaled corticosteroids inpressurizedmetered does inhalers (pMDIs) are often deliveredvia a large volume
spacerdevice, butthese arebulkyandinconvenient.Drypowderinhalers (DPIs) provide ahighlyportable andconvenient
propellant-free alternative to pMDIs for asthmamaintenance therapy.However, each DPIcouldhave unique in vivodeliv-
erycharacteristics.Inorder to quantify thetotalandregionallungdepositionof budesonide (200 mg) from (a) Easyhaler1,
(b) Turbuhaler1and (c) pMDIplusNebuhaler1750mlspacer, athree-wayrandomizedcross-over studywascarriedout
in12 mild to moderate asthmatic patients.Depositionwas quanti¢ed by the imaging technique of gamma scintigraphy.
Optimal inhalationtechniqueswere used throughout.Mean (SD) whole lungdeposition (% metered dose) was similar for
Easyhaler1 [18?5 (7?8) %] and Turbuhaler1 [21?8 (8?2) %], but was signi¢cantly higher for pMDIplus Nebuhaler1 [44?1
(10?0) %, P50?01].The regional distribution patterns in the lungswere predominantly central for all three devices. Neb-
uhaler1 reduced oropharyngeal deposition signi¢cantly comparedwiththe two DPIs.Easyhaler1 Showed comparable
depositiontoTurbuhaler1andhence drugsdeliveredby Easyhaler1wouldbe expectedtohave a similarclinicale¡ectto
those delivered byTurbuhaler1 in asthmamaintenance therapy.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1107, available online at http://www.idealibrary.comon
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The Montreal Protocol on substances that deplete the
ozone layer has led to the developmentof inhaler devices
for the delivery of asthma drugs that do not rely upon
the use of chloro£uorocarbon (CFC) propellants (1^3).
Dry powder inhalers (DPIs) have been prominent
amongst these developments, andmany newmulti-dose
devices have been described (4). The ¢rst of these was
Turbuhaler1 (AstraZeneca, Sweden), introduced origin-
ally for the delivery of terbutaline sulphate and budeso-
nide. Easyhaler1 (Orion Pharma, Finland) is a new-
generation DPI developed to combine the familiar shapeReceived14 November 2000 and accepted in revised form 27 March
2001.
Correspondence should be addressed to:Dr P.H.Hirst,
Pharmaceutical Pro¢les Ltd,Mere,Way,Ruddington Fields,Ruddington,
NottinghamNG116JS,U.K.Fax: (44) 115 974 8000;
E-mail:phirst@pharmpro¢les.co.ukof the pressurizedmetereddoes inhaler (pMDI) with the
bene¢ts of dry-powder drug delivery (Fig.1).
Pressurizedmetered dose inhalers have been the tra-
ditional means of delivering inhaled asthma drugs. For
inhaled corticosteroids such as budesonide, it is recom-
mended that pMDIs are used in conjunction with a large
volume spacer device for the delivery of any dose in chil-
dren, and for doses 4800mg daily in adults (5). Spacer
devices reduce the total body dose of inhaled corticos-
teroids (6), which may result in fewer local and systemic
side-e¡ects. In addition, spacers are able to reduce the
problems of co-ordination that many patients have with
standard pMDIs.However, large volume spacers lack the
portability and convenience of DPIs.Owing to environ-
mental concerns, pMDIs are currently being reformu-
lated with hydro£uoroalkane (HFA) propellants (7)
although for many products, this process has been tech-
nically challenging. As a result, dry powder inhalers pro-
vide an attractive alternative to conventional pMDIs
used either with or without a spacer.
FIG. 1. Easyhaler1multi-dose dry-powder inhaler.
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mined in part by the total amount of drug deposited in
the lungs, and its distribution amongst airways of di¡er-
ent sizes (8). Hence, the objective of this study was to
compare in a group of patients with mild to moderate
asthma, the deposition of the corticosteroid budesonide
inhaled via Easyhaler1 with two of the most commonly
used inhaler systems for inhaled budesonide: Turbuha-TABLE 1. Demographic details ofthe studypopulation of asthm
Number Age (years) Sex Height (m) FEV
1 59 M 1?80
2 55 M 1?66
3 31 M 1?82
4 51 M 1?79
5 36 M 1?80
6 21 F 1?58
7 41 F 1?45
8 37 M 1?72
9 40 M 1?83
10 18 M 1?86
11 38 F 1?85
12 30 F 1?68
Mean 38 1?74
SD 13 0?12ler1 and pMDI plus Nebuhaler1 large volume spacer.
The latter device was included in the comparison with
the two DPIs as a reference standard.Total and regional
deposition of budesonide were quanti¢ed by the radio-
nuclide imaging technique of gamma scintigraphy (9,10).
METHODS
Patients studied
The study was a three-way randomized cross-over in-
vestigation in12 patients with mild to moderate asthma,
who inhaled on di¡erent study days a single dose of
200mg budesonide from (a) Easyhaler1 (b) Turbuhaler1
and (c) pMDI coupled to a Nebuhaler1 750ml
spacer. Successive dosings were separated by at least
48h. The demographic details of the patients are
shown inTable 1. Eight were male and four were female.
The ages of the subjects ranged from 18 to 59 years,
and their forced expiratory volumes in 1sec (FEV1)
varied from 64 to 102% of the predicted value based
on age, sex and height (11). Prior to the study, each
subject was medically screened to ensure that they met
the inclusion and exclusion criteria for the study, and
written consent to take part in the study was given fol-
lowing explanation of the study procedures. The study
was approved by the Quorn Research Review Commit-
tee, Leicestershire, U.K. and approval to administer
radioactive substances was given by the Department of
Health,U.K.
Radiolabelling of formulations
In order to assess deposition of budesonide in the
asthmatic patients it was ¢rst necessary to establish
and validate appropriate radiolabellingmethods for eachatic patients
1 (l) Measured FEV1 (l) Predicted FEV1% Predicted
2?67 3?54 75
1?95 3?05 64
3?69 4?44 83
2?86 3?73 77
2?89 4?21 68
2?77 3?02 91
1?92 2?10 91
3?58 3?83 93
2?89 4?22 68
4?58 4?78 96
2?98 2?93 102
2?60 3?29 79
2?95 3?60 82
0?73 0?76 12
722 RESPIRATORYMEDICINEformulation using the radionuclide 99mTc. For Turbuha-
ler1, a method was used based on that described by
Thorsson et al. (12), in which 99mTc was extracted into
methyl ethylketone (MEK), which was then evaporated.
The radiolabel was taken up in distilledwater and added
to budesonide drug spheres taken from a commercially
marketed Turbuhaler1. Following freeze-drying, the
radiolabelled powder was returned to theTurbuhaler1.
The freeze-drying procedure was developed speci¢cally
for the radiolabelling process and is not used in the
manufacture of the commercial product. Hence, the
radiolabelledproductwas not identical to that approved
in the product licence.
For the Easyhaler1, the radiolabelling method was
based on that described previously for this device (13),
and resembled thoseused for radiolabelling the contents
of several otherDPIswhere theproduct is formulated as
a blend of micronized drug and lactose (14,15).The radio-
nuclide 99mTc was again extracted into MEK, and thence
into water, and was then added to micronized budeso-
nide. After freeze-drying, the radiolabelled budesonide
powder was passed through a150mm sieve and blended
with lactose in aTurbula 2TCmixer. Aswith theTurbuha-
ler1, the freeze-dryingprocedurewas developed for the
radiolabelling process and is notused in themanufacture
of the commercial product.
For the pMDI, the method previously described by
Summers et al. (16) was used, the radionuclide being ex-
tracted into MEK, added to an empty pMDI canister and
the MEKevaporated.The contents of a ¢lled budesonide
canister (Pulmicort1, AstraZeneca) that had been
cooled to below 7608C were added and a metering
valve was crimped in place. A metered dose from each
device contained a maximum of10MBq 99mTc.
Prior to commencement of the in vivo study, radiola-
belling validation experiments were carried out in order
to show that the 99mTc radiolabel was a validmarker for
the drug across the full range of particle size bands. For
each of the three products, the size distributions of drug
before labelling, drug after labelling and 99mTc radiolabel
were determined.For the twoDPIs, these datawere ob-
tained from particle sizing experiments with a High Pre-
cision Multi-stage Liquid Impinger (HPMLI), while an
Andersen sampler was used to obtain similar data for
the pMDI (17,18).The HPMLI and Andersen sampler were
¢ttedwith aUSP induction port or throat (19).These siz-
ing devices fractionate the aerosol cloud according to
particle size, while air is drawn through the device at a
¢xed £ow rate (60 lmin71 for HPMLI; 28?3 lmin71 for
Andersen sampler).The DPIs were tested with pressure
drops across each device of 4 kPa, which corresponds to
the pressure drop obtained when an ‘average’ person in-
hales with maximum e¡ort.The 4kPa pressure drop re-
sulted in £ow rates of 60 lmin71 for Turbuhaler1 and
58 lmin71 for Easyhaler1.The ¢ne particle fraction was
measured as drug or radiolabel recovered from stages 3,4 plus ¢nal ¢lter for HPMLI, and from stages 2 to ¢nal
¢lter in the Andersen sampler. Fine particle mass was
quanti¢ed from the mass of drug recovered from the
same stages. For each treatment regimen,10 doses were
¢red from primed devices into the impinger apparatus.
The stages were quantitatively washed with an appro-
priate solvent into 50ml volumetric £asks, and amounts
of drug and radiolabel washed from each stage were de-
termined by ultraviolet (UV) spectrophotometry at a
wavelength of 243nm, and by gamma counting, respec-
tively. The total mass of drug recovered in each experi-
ment was compared with the nominal dose in order to
derive a percentage recovery ¢gure. The pMDI was
tested alone without a Nebuhaler1 attached, as pre-
vious studies have demonstrated that addition of a
spacer device does not a¡ect the quality of the radio-
labelling (13).
In vivo study days
Inhalations were carried out with the inhaler devices
connected in series with a Vitalograph MDI-Compact
Spirometer, allowing inhaled £ow rate, inhaled volume
andbreath-holdingpause to berecorded.Prior to admin-
istration of the radiolabelled formulations on each study
day, subjects practiced the inhalation manoeuvre with
the aid of an emptydevice.Patientswere taught to inhale
at an average inhalation rate of approximately 30 lmin71
for the MDI plus spacer, and at a peak inhalation rate of
approximately 60 lmin7 for Easyhaler1 and Turbuha-
ler1. For the two DPIs, this £ow rate represented max-
imal inspiratory e¡ort corresponding to a pressure drop
of approximately 4kPa.Once the investigator was sure
that a patient hadmastered the required technique, the
empty inhaler was replaced with the radiolabelled inha-
ler and the dosing took place. For the pMDI plus spacer,
the devicewas ¢redby an investigator, and inhalation be-
gan 1sec later. For each regimen, breath was held for
10 sec on completion of inhalation, and then the subject
exhaled via a ¢lter to trap exhaled particles. All inhalers
were primed by ¢ring 10 shots to waste shortly before
dosing.The spacers were removed from their packaging
on themorningof each studyday, assembledand allowing
to stand for several hours before they were used. They
were handled without gloves in order to minimize the
generation of static charge.
Oncompletion of dosing, subjectswere imaged imme-
diatelyby aGeneral ElectricMaxi camera connected to a
Bartec Micas V data processing system. Anterior and
posterior lung images (100 sec) and a lateral oropharynx
image (30 sec) were obtained. Where appropriate,
images were also taken of the Easyhaler1 mouthpiece,
the Turbuhaler1 mouthpiece, the pMDI actuator plus
Nebuhaler1 spacer and the exhaled air ¢lter.On a single
occasion, each subject had a ventilation scan using 81mKr,
in order to de¢ne the lung borders, and the lungs were
FIG. 3. Distribution of drug before labelling (n=5, ) after la-
belling (n=13, ) and radiolabel (n=13, ) in an HPMLI for the
Turbuhaler1.MP: mouthpiece;Thr: ‘throat’; S1 to S4: stages 1 to
4;Fil: ¢nal ¢lter.
LUNGDEPOSITIONOFBUDESONIDEFROM THREE INHALERDEVICES 723divided into central, intermediate and peripheral regions
based on a pre-determined template (9). After subtrac-
tion of radioactive background, the geometric means of
anterior and posterior lung and stomach counts were
calculated, and lung, stomach and oropharyngeal images
were corrected for the e¡ects of gamma ray attenuation
(20). Deposition data were expressed as percentages of
themetered dose for each product.The total corrected
counts in lungs, oropharynx, stomach, inhaler device,
and ¢lter were summed, and percentage deposition in
each site was calculated as a percentage of the total
count. Counts in the stomach were assumed to have
arisen from swallowed radioactivity initially deposed in
the oropharynx.
As a safety measure, measurements of lung function
[FEV1, forced vital capacity (FVC), and peak expiratory
£owrate (PEFR)]weremeasuredbefore dosing, and then
60min later by theVitalograph Compact Spirometer.
The Wilcoxon matched-pairs signed ranks test was
used to determinewhether di¡erences between deposi-
tion parameters for the three regimens were signi¢cant.
A P value of 0?05 was considered signi¢cant.
RESULTS
Radiolabelling validation data
The size distributions of drug before labelling, drug after
labelling, and 99mTcradiolabel are shownin Figs 2, 3 and 4
for Easyhaler1,Turbuhaler1 and pMDI respectively.Fine
particle dose, ¢ne particle mass and drug recovery are
listed inTable 2. For Easyhaler1, the FPF of drug before
labelling (mean 35?9%) averaged higher than the FPF of
the radiolabel (mean 30?0%). For Turbuhaler1, FPFs for
drug and label matched well, but there was less radiola-FIG. 2. Distribution of drug before labelling (n=4, ) after la-
belling (n=5, ) and radiolabel (n=5, ) in an HPMLI for Easyha-
ler1.MP:mouthpiece;Thr:‘throat’;S1to S4: stages1to 4;Fil: ¢nal
¢lter.bel than drug on the mouthpiece, and more radiolabel
than drug on stage 1 of the impinger. These di¡erences
were restricted to very large particles (413mm), which
would be expected to deposit in the upper airways and
not to penetrate to the lungs, so that therewould be no
signi¢cant in£uence on the primary endpoint of lung de-
position.The reduction in drugdeposition on themouth-
piece and increased deposition on stage1may have been
a result of some of the large spheronized particles being
broken down during the radiolabelling process. The
pMDI showed a good match between the size distribu-
tions of drug before labelling, drug after labelling, and
radiolabel, although the FPF of the drug before labelling
(mean 24?5%) averaged lower than the FPF of the radi-
olabel (mean 28?5%).FIG. 4. Distribution of drug before labelling (n=5, ) after la-
belling (n=5, ) and radiolabel (n=5, ) in an Andersen sampler
for the pMDI.Act: actuator;Thr:‘throat’; S0 to S7: stages 0 to 7;
Fil: ¢nal ¢lter.
TABLE 2. Radiolabelling validation data.Mean (SD) ¢ne particle fraction (FPF), ¢ne particle mass (FPM), and drug recovery
expressed as a percentage of the nominalmetered dose, for the three treatment regimens, showing data for drug before, and
afterradiolabelling, and for the 99mTcradiolabel.Massmedianaerodynamicdiameters (MMADs) andgeometric standarddevia-
tions (GSDs) are also provided.
FPF (%) FPM (mg) Drugrecovery (%) MMAD,mm (GSD)
Easyhaler1
Drugbefore (n=4) 35?9 (4.6) 74?6 (7?5) 104?3 (8.3) 4 (2)
Drugafter (n=5) 32?3 (3?6) 62?5 (7?8) 96?8 (7?2) 4 (2)
Radiolabel (n=5) 30?0 (3?33) n/a n/a 4 (2)
Turbuhaler1
Drugbefore (n=5) 34?1 (2?6) 70?7 (10?0) 103?2 (7?2) 3 (2)
Drugafter (n=13) 38?1 (2.4) 69?3 (9?2) 91?3 (12?8) 3 (2)
Radiolabel (n=13) 34?1 (5?1) n/a n/a 3 (2)
pMDI
Drugbefore (n=5) 24?5 (1?6) 52?6 (5.1) 107?2 (6.7) 3 (3)
Drugafter (n=5) 26?2 (1?3) 56?2 (2?3) 94?7 (1?1) 3 (3)
Radiolabel (n=5) 28?5 (1?6) n/a n/a 2 (3)
TABLE 3. Mean (SD) percentage of themetered dose of budesonide (200 mg) deposited in the lungs and oropharynx, retained
on the inhaler device and recovered from the exhaled air, in12 asthmatic patients inhaling from Easyhaler1,Turbuhaler1 and
pMDIcoupled to Nebuhaler1 spacer
Easyhaler1 Turbuhaler1 pMDI+Nebuhaler1
Whole lung 18?5 (7?8)* 21?8 (8?2)* 44?1 (10?0)
Oropharynx 73?6 (13?8)*{ 61?8 (10?9)* 14?1 (7?2)
DPImouthpiece 7?8 (13?6) 16?0 (9?7) n/a
pMDI actuator n/a n/a 7?4 (4?2)
Spacer n/a n/a 33?5 (7?7)
Exhaled air ¢lter 0?1 (0?3) 0?4 (0?3) 1?8 (1?2)
*P50?01vs. pMDIplus Nebuhaler1.
{ P50?05 vs.Turbuhaler1.
724 RESPIRATORYMEDICINEOn the basis of these results, the radiolabelling data
demonstrated that there were some di¡erences be-
tween the PSDs of the unlabelled drug, radiolabelled
drug andradiolabel.However, these di¡erenceswere suf-
¢ciently small for meaningful clinical conclusions to be
drawn, and it was judged appropriate to proceed to a
scintigraphic study.These data were supported by calcu-
lating the mass mean aerodynamic diameters (MMADs)
and geometric standard deviations (GSDs) for each of
the three formulations (Table 2). For the Easyhaler1
and Turbuhaler1 formulations, the MMADs were un-
changed for the drug before radiolabelling, drug after la-
belling and radiolabel (MMADs were 4mm and 3mm for
the Easyhaler1 and Turbuhaler1, respectively). For the
pMDI, the MMAD for the drug before and after radiola-
belling was 3mm and the MMAD for the radiolabel was
2mm. The MMADs for the pMDI were lower than ex-
pected given the low FPFs, however, it has been demon-strated that fractional deposition becomes almost
independent of MMADwhen the GSD is high (21).
Scintigraphic data
The in vivo fractionation of the metered dose between
lungs, oropharynx, inhaler device and exhaled air is
shown inTable 3.There was no signi¢cant di¡erence be-
tween the mean (SD) whole lung deposition for Easyha-
ler1 [18?5 (7?8)%] and for Turbuhaler1 [21?8 (8?2)%].
However, both of these values were signi¢cantly less
than whole lung deposition with pMDI plus Nebuhaler1
[44?1 (10?0)%, P50?01]. Oropharyngeal deposition was
greater for Easyhaler1 [73?6 (13?8)%] than forTurbuha-
ler1 [61?8 (10?9)%,P50?05], and the pMDI plus Nebuha-
ler1 had the lowest oropharyngeal deposition [14?1
(7?2)%,P50?01].The remainder of the dosewas retained
TABLE 5. Inhalation details and changes in FEV1for eachtreatmentregimen.Data aremean (SD)
Easyhaler1 Turbuhaler1 pMDI+Nebuhaler1
Peak inhaled £ow (lmin71) 63 (6) 64 (10) 44 (19)
Average inhaled £ow (lmin71) n/a n/a 27 (14)
Inhaledvolume (l) 3?11 (1?02) 3?32 (0?90) 1?91 (0?59)
Breathhold (sec) 9?7 (0?5) 10?4 (0?8) 10?8 (1?6)
FEV1 (l) pre-dose 2?83 (0?87) 2?84 (0?88) 2?91 (0?90)
FEV1 (l) post-dose 2?88 (0?87) 2?80 (0?85) 2?84 (0?90)
TABLE 4. Regional lung deposition data: percentage of metered dose deposited in central, intermediate and peripheral lung
zones, andperipheral zone/central zone depositionratio (P/Cratio).Data aremean (SD)
Easyhaler1 Turbuhaler1 pMDI+Nebuhaler1
Central zone (%) 7?3 (3?2)* 8?5 (3?9)* 16?2 (5?5)
Intermediate zone (%) 6?1 (2?5)* 7?4 (2?7)* 15?3 (4?0)
Peripheral zone (%) 5?1 (2?7)* 5?9 (2?3)* 12?6 (4?5)
P/Cratio 0?8 (0?3) 0?8 (0?4) 0?9 (0?5)
*P50?01vs.pMDIplus Nebuhaler1.
LUNGDEPOSITIONOFBUDESONIDEFROM THREE INHALERDEVICES 725on the inhaler devices, with a very small amountexhaled.
Retention on the body of the Nebuhaler1 spacer was
33?5 (7?7)% of the dose.
Deposition in each of theperipheral, intermediate and
central lung regions (Table 4) showed a similar trend to
the whole lung deposition, with similar depositions for
Easyhaler1 and Turbuhaler1, but signi¢cantly higher de-
position in each zone for pMDI plus spacer (P50?01).The
peripheral zone/central zone deposition ratio (P/C ratio)
was similar for each of the threeregimens (Table 4), aver-
aging 0?8 for Easyhaler1 and Turbuhaler1, and 0?9 for
pMDI plus Nebuhaler1.
Inhalation details and lung function changes
Thepeak inhaled £owrates through Easyhaler1 andTur-
buhaler1 averaged 63 lmin71 and 64 lmin71 respec-
tively, while the average inhaled £ow rate through the
pMDI plus Nebuhaler1 averaged 27 lmin71 (Table 5).
These were very close to the targeted values of 60, 60
and 30 lmin71for the three devices, respectively. Inhaled
volumeswere somewhathigher for the twoDPIs.Breath
holding valueswere close to the targetedvalues of10 sec.
Lung function was unchanged 60min after inhalation of
the budesonide formulations, and there were no inci-
dents of signi¢cant bronchoconstriction. Only FEV1 va-
lues are presented in Table 5, but FVC and PEFR also
showed no changes after dosing.DISCUSSION
Dry powder inhalers have two important advantages
over pressurized metered dose inhalers (pMDIs). The
use of environmentally damaging chemicals such asCFCs
is avoided, and the powder formulation is dispersed by
the act of inhaling, without the need to ‘press and
breathe’ simultaneously. The earliest DPIs were single
dose devices, but the introduction of Turbuhaler1, Easy-
haler1, and othermulti-dose devices has been an impor-
tant step forward in themaintenance therapy of asthma.
Easyhaler1 is a highly reproducible DPI (22) resulting
in a similar bronchodilator response to salbutamol com-
pared with that obtained from either a pMDI alone (24,
23) or pMDI plus large volume spacer device (21). Equiva-
lence of e⁄cacy and safety have been shown for 800mg
daily beclomethasone dipropionate (BDP) delivered by
Easyhaler1 and by pMDI plusVolumatic1 spacer in ster-
oid-naiºve asthmatics (24). Importantly, Easyhaler1 has
been shown to be easier to use andpreferredbypatients
in comparisonwithTurbuhaler1 and pMDI (25).
In previous scintigraphic, studies, mean lung deposi-
tion of salbutamol from Easyhaler1 averaged 28?9% of
the metered dose in healthy volunteers (21,26) and
24?0% in asthmatics (27), while for BDP, lung deposition
in asthmatic patients averaged18?9% of the dose (13). By
comparison, mean lung deposition from theTurbuhaler1
with optimal inhalation technique, expressed as a per-
centage of the metered dose, has been estimated
726 RESPIRATORYMEDICINEvariously as14?2% (28),16?8% (29),19?0% and 22?0% (30),
21?4% (31), 27?0% and 27?7% (32) and 32?0% (33).
Although these mean values for Turbuhaler1 varied
somewhat from study, to study therewasno obvious sys-
tematic e¡ect of the type of volunteer (healthy subjects
vs. asthmatics), choice of method to assess lung deposi-
tion (gamma scintigraphy vs. pharmacokinetic method)
or the nature of the drug formulation (a highly water so-
luble, drug, terbutaline sulphate, or a much less water
soluble drug, budesonide).On the basis of previous data,
therewas reason to expect similar lungdepositions from
the two DPIs in the present study, a prediction that this
head-to-head comparison has con¢rmed.
Before starting the clinical phase of the study, it was
¢rst necessary to develop radiolabelling methods for
each of the three devices. Some of the processes used
in the radiolabellingprocesswere di¡erent to thoseused
in the manufacture of the commercial product. As a re-
sult it was important to demonstrate that the particle
size distributions of the radiolabelled drug were repre-
sentative of the non-radiolabelled products and that for
each product, the radiolabel acted as a valid marker for
the drug. In each case, the radiolabel distributions of the
radiolabelled products were slightly di¡erent to the par-
ticle size distributions of the non-radiolabelled product.
However, these di¡erences were su⁄ciently small for
meaningful clinical conclusions to be drawn. During the
course of the radiolabelling development, some radiola-
belled Turbuhalers1 had radiolabel distributions that
were outside the range of those observed for non-radi-
olabelled Turbuhalers1. As a result, all radiolabelledTur-
buhalers1were testedbefore dosing to con¢rm that the
radiolabel distribution was comparable to the non-radi-
olabelled product.This variability was not observed for
the Easyhaler1 and pDMI therefore these were not
tested before dosing.
The radiolabelling validation data for the Easyhaler1
showed a slightly higher ¢ne particle fraction for drug
than radiolabel, so that the mean lung deposition value
of 18?5% of the drug dose might have been a slight un-
der-estimate, bringing its true value even closer to that
of the Turbuhaler1. The pMDI plus Nebuhaler1 pro-
duced the highest lung deposition in the study. Spacers
invariably reduce oropharyngeal deposition and may in-
crease lung deposition compared with a pMDI alone
(6,34).High lung deposition (430% of themetered dose)
has been reported previously for the Nebuhaler1 (35^
37), especially when used under optimal conditions.
When the depositions of budesonidewere compared di-
rectly (37), lung deposition was higher for the Nebuha-
ler1 (mean 38?4%) than Turbuhaler1 (mean 26?1%). By
contrast, in two clinical studies in children, where the
bene¢cial e¡ects and side-e¡ects e¡ects of budesonide
were assessed, Turbuhaler1 was shown to be either
equivalent to Nebuhaler1 (38), or equally e¡ective in a
smaller dose (39). The mean lung deposition value forthe pMDI plus Nebuhaler1 (44?1% of the dose) observed
in this study could have been an overestimate, owing to
the slight mismatch between ¢ne particle fractions of
drug and radiolabel.
The radiolabelling data obtained for theTurbuhaler1
indicate that despite the mismatch between the radiola-
bel and non-labelled drug on the mouthpiece of theTur-
buhaler1 and stage1of the MSLI, therewas a very good
match on the remaining stages of the MSLI. As a result,
themean lung deposition of 21?8% observed in this study
was a true re£ection of in vivo lung deposition.
The e⁄ciency of large volume spacers depends heavily
upon control of electrostatic charge e¡ects, which may
cause drug delivery to very considerably according to
how the spacer is handled and when it was last washed
(40^42).The results of both deposition studies and clin-
ical response studies are likely to dependupon the speci-
¢c handling technique used for the spacer. In a previous
scintigraphic study (13) Easyhaler1 produced signi¢-
cantly higher lung deposition of BDP than pMDI plus Vo-
lumatic1 spacer in adult asthmatic patients, when no
special steps were taken to minimize static charge on
the spacer walls. In that study, spacers were used imme-
diately after being taken from their packaging, whereas
in the present study, they were removed from their
packaging and allowed to stand for several hours before
use. In addition, they were handledwithout gloves in the
present study, in order to keep generation of static
charge to a minimum. Warren and Taylor (43) showed
that lung deposition of BDP from another DPI (Clickha-
ler1,ML Laboratories,U.K.) was higher than that from a
pMDI plus Volumatic1 spacer. Each brand of spacer de-
vice has di¡erent drug delivery characteristics, and it is
possible that the Nebuhaler1 is an inherentlymore e⁄-
cient device than the Volumatic1, which would help to
explain the superior pulmonary delivery data obtained
with the Nebuhaler1.
While some spacer devices may be very e⁄cient in
their delivery characteristics, they are also very bulky,
and compared to DPIs are much less convenient to use
for regular asthmamaintenance therapy.Dry powder in-
halers aremuchmore portable and convenient.The data
from the present study suggest that Easyhaler1 has
comparable in vivo drug delivery characteristics toTurbu-
haler1. The two devices would be likely to have similar
e¡ect and side-e¡ect pro¢les in clinical practice when
used in equivalent doses. Clinical trials are currently in
progress to verify this hypothesis.
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